Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Melanoma 21Carcinoma, Renal Cell 21Neoplasms 8Lung Neoplasms 8Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Neoplasm Metastasis 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Stomach Neoplasms 5Rectal Neoplasms 5Hodgkin Disease 5Adenocarcinoma Of Esophagus 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Nasopharyngeal Carcinoma 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Colonic Neoplasms 3Brain Neoplasms 3Anus Neoplasms 3

Interventions

atezolizumab 2tocilizumab 1spartalizumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1adagrasib 1Trastuzumab 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Docetaxel 1Cyclophosphamide 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × Nivolumab × 30 days × Clear all
NCT07176975 2026-05-26

A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

Boehringer Ingelheim

Phase 1 Not yet recruiting
46 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡